GlassScriptPhysician profile
David J Etzel
NPI 1881999555
$2,763.89
in general payments reported to CMS, 2019-2025
21 companies · $851 in 2025
The $851 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $319 · 2023: $827 · 2024: $233 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $682.79 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $648.15 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $206.42 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $179.98 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $150.00 | 2021-2024 | Mounjaro |
| Pfizer INC. | $126.87 | 2021-2025 | |
| Alkermes, INC. | $110.09 | 2021-2025 | Vivitrol, Vivitrol |
| Indivior INC. | $88.49 | 2021-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.03 | 2022-2023 | Trulance, Xifaxan |
| Xeris Pharmaceuticals, INC. | $84.31 | 2023-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.26 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $60.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $60.41 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $52.58 | 2022-2023 | |
| Abbott Laboratories | $32.54 | 2025 | Freestyle Libre 3 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.02 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.09 | 2021 | |
| Gilead Sciences, INC. | $18.69 | 2023 | |
| Braeburn INC. | $16.70 | 2025 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $15.27 | 2022 | |
| Exact Sciences Corporation | $13.53 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Etzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.